HIT Consultant August 1, 2024
What You Should Know:
– Outpace Bio, a pioneering cell therapy company raises $144M in oversubscribed Series B financing round led by RA Capital Management with participation from both new and existing investors, including Qatar Investment Authority, Surveyor Capital, Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments, and several others. Outpace has now raised a total of approximately $200M to date.
– Jake Simson, Partner at RA Capital Management, will join Outpace Bio’s Board of Directors.
Transforming Cancer Treatment with AI-Powered Cell Therapy
Outpace Bio is focused on revolutionizing cancer treatment through its AI-powered protein design platform. The company’s proprietary technology enables the creation of engineered T cells with enhanced capabilities, such as improved tumor infiltration, extended persistence, and...
Today's Sponsors
Today's Sponsor